ZipRecruiter delivered its sharpest weekly gain of the year this week, rising 17% to $3.62 after first-quarter results triggered a 16% single-day jump on May 8. The move puts the stock up 83% from a month ago — a striking recovery from a name that the Street has steadily downgraded over the past year.
The earnings reaction itself was the catalyst, and it was decisive. The stock's 16% move on Thursday was the only post-earnings data point in the recent history window, and it came after analysts had been cutting targets aggressively throughout late 2025 and early 2026. With the next event pencilled in for June 9, the market has roughly a month to digest a Q1 beat before the next test arrives.
Options traders are leaning into the recovery rather than hedging against it. The put/call ratio has collapsed to 0.11 — near its 52-week low of 0.03 — and sits well below its 20-day average of 0.23. That reflects a market buying calls or simply not buying puts: directional optimism, not defensive positioning. The contrast with conditions in early April is sharp: the PCR ran above 0.60 for most of that month as the stock languished below $2. That overhang has cleared.
Short positioning is a measured subplot, not the headline. Short interest at 6.7% of free float is meaningful but easing — it fell 2.3% week-on-week and was higher a month ago at roughly 6.8%. Availability in the lending pool is ample, with cost to borrow at 0.83% and falling — down 20% on the week and 30% over the past month. There is no squeeze pressure here. The borrow market is relaxed, which means the bounce is being driven by buyers stepping in, not by forced short covering.
The Street's reaction to the earnings beat has been cautious optimism at best. UBS, which cut its target from $4.50 to $2.50 in February after the prior quarter, raised it back to $3.50 on May 8, keeping a Neutral rating. That target is now just below the current price. Prior to this week, every major analyst action over the past year — from UBS, Barclays, Goldman Sachs, and JPMorgan — was a target cut, with Goldman and JPMorgan both slashing from $7 to $5 in August 2025. The consensus target of $3.33 now sits fractionally below where the stock is trading, and no analyst has upgraded the rating itself to Buy. Fundamentally, the latest quarterly numbers offer context: revenue of $107.5 million was down 2.3% year-on-year, gross margins were high at 88.9%, but EBITDA was barely above breakeven at $1.3 million, and the company carried $557 million of debt against $251 million of cash.
The CEO founder Ian Siegel has been selling steadily — roughly 9,700 shares each week since at least mid-March, including three trades in the first week of May alone at prices between $3.06 and $3.23. These are small in absolute dollar terms (under $32k per trade) and look like a pre-set plan, but the consistency of the cadence is worth noting. The Siegel Family Trust remains the largest single holder at 16% of shares, which keeps founder alignment high even as the routine sales continue. Among institutional holders, Edmond de Rothschild and Disciplined Growth Investors both added materially in Q1, while ArrowMark trimmed.
With the PCR at a near-annual low, shorts easing, and the UBS target already below spot price, what matters next is whether the June 9 print confirms any stabilisation in the revenue trend — or reveals that Q1's beat was a one-quarter event.
See the live data behind this article on ORTEX.
Open ZIP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
